Restless Leg Syndrome: Treatment Options Explained

The Dopamine Trap: Why First-Line Therapy Shifted

Restless leg syndrome (RLS), formally called Willis-Ekbom disease, affects 7–10% of the US population and is the second most common sleep disorder after insomnia. For two decades, dopamine agonists like pramipexole and ropinirole were the go-to prescription. Then clinicians noticed a disturbing pattern: patients who started on low doses required progressively higher doses over months to years, and their symptoms paradoxically worsened. This phenomenon — dopaminergic augmentation — now affects up to 68% of patients on long-term dopamine agonist therapy. The medical community reclassified these drugs from first-line to last-resort for most cases.

What Augmentation Looks Like

Augmentation is not simple tolerance. It is a clinical syndrome with specific hallmarks: symptoms begin earlier in the day (spreading from evening to afternoon or morning), the urge to move spreads from the legs to the arms or torso, and the intensity of symptoms increases. The International RLS Study Group (IRLSSG) published revised diagnostic criteria for augmentation in 2016. Shorter-acting dopamine agonists carry higher augmentation risk than the rotigotine patch, which delivers continuous dopaminergic stimulation.

Iron: The Overlooked Root Cause

Iron deficiency in the brain — specifically in the substantia nigra and putamen — is now considered a central mechanism in RLS pathophysiology. Critically, standard serum iron tests miss this. The relevant marker is serum ferritin. Ferritin below 75 ng/mL is considered the treatment threshold by current guidelines, even if standard iron panels appear normal. In patients with ferritin under 75, IV or oral iron supplementation alone can produce significant or complete symptom resolution.

• Oral iron: ferrous sulfate 325 mg with vitamin C on an empty stomach, taken every other day to maximize absorption
• IV iron: iron sucrose or ferric carboxymaltose preferred for those who cannot tolerate oral supplementation or have malabsorption
• Target ferritin: most guidelines recommend raising ferritin to 100–300 ng/mL before concluding iron therapy is ineffective
• Dialysis patients: RLS prevalence reaches 20–40% in end-stage renal disease; IV iron is standard in this population

Why Every Other Day Oral Iron?

A 2017 study in Blood demonstrated that daily oral iron suppresses hepcidin for about 24 hours, which paradoxically reduces iron absorption the following day. Alternate-day dosing keeps hepcidin levels lower and increases net absorption by roughly 40% compared to daily dosing. This pharmacological nuance is often missed in practice.

Alpha-2-Delta Ligands: The New Standard

Current IRLSSG and American Academy of Sleep Medicine guidelines now recommend alpha-2-delta calcium channel ligands as preferred first-line pharmacotherapy for moderate-to-severe RLS. These drugs — gabapentin, pregabalin, and the RLS-specific formulation gabapentin enacarbil — work by reducing neuronal excitability in sensory pathways, addressing the hyperexcitability thought to underlie the sensory-motor symptoms of RLS.

Gabapentin enacarbil is a prodrug: it is absorbed via active transport in the intestine and converted to gabapentin in the body, bypassing the saturable absorption that limits standard gabapentin. In clinical trials, it reduced IRLS scores by an average of 13 points versus placebo. Key side effects include dizziness and somnolence; the drug carries a boxed warning for driving impairment.

Dopamine Agonists: When and How to Use Them

Despite their demotion, dopamine agonists retain a role in patients who fail or cannot tolerate alpha-2-delta ligands. The rotigotine transdermal patch (Neupro) has the lowest augmentation risk among available options due to its continuous delivery profile. Pramipexole and ropinirole, taken orally before bedtime, are reserved for intermittent RLS or short-term use.

Discontinuing dopamine agonists after augmentation is notoriously difficult. Withdrawal produces a temporary but severe worsening of symptoms — sometimes called "rebound" — lasting days to weeks. Tapering over 3–6 months while bridging with an alpha-2-delta ligand or low-dose opioid (such as oxycodone or methadone in refractory cases) is the standard approach.

Non-Pharmacological and Lifestyle Strategies

Not every RLS patient needs medication. Mild RLS often responds to lifestyle modification. Caffeine and alcohol reliably worsen RLS symptoms and should be minimized. Several common medications — antidepressants (particularly SSRIs and TCAs), antihistamines, antipsychotics, and antiemetics — can precipitate or worsen RLS by blocking dopamine receptors; reviewing the medication list is essential at every visit.

• Pneumatic compression devices: a 2013 randomized trial showed significant IRLS score reduction, possibly by improving venous return and dopamine bioavailability
• Near-infrared light therapy: preliminary evidence suggests benefit, mechanism unclear
• Vigorous exercise earlier in the day: associated with symptom reduction, though late-evening exercise can worsen symptoms acutely
• Heat and cold application to the legs immediately before bedtime
• Cognitive behavioral therapy for the associated insomnia, which affects 95% of severe RLS patients

Pregnancy and RLS

RLS occurs in approximately 26% of pregnancies, typically in the third trimester, and resolves spontaneously postpartum. Pharmacological options are severely limited due to fetal safety concerns. IV iron is the primary treatment when ferritin is below 75 ng/mL. Folate supplementation has shown modest benefit in some studies.

This article is for informational purposes only. Consult a qualified healthcare professional.